Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Study sponsor: Cartesian Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-02-18Actual
Enrollment · participants5Actual
Source updated2024-12-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.